Navigation Links
FDA Approves Marketing of RMS Subcutaneous Needle Sets
Date:6/1/2011

CHESTER, N.Y., June 1, 2011 /PRNewswire/ -- Repro-Med Systems, Inc., (REPR.PK) announced today that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo™ RMS Subcutaneous Needle Sets.  The needle sets are intended for the delivery of medication to subcutaneous tissue.  The needle sets have previously been approved and available for use by patients in Canada and Europe.  Repro-Med Systems, Inc. utilizes the name RMS Medical Products.

"The FDA's approval allows patients here in the U.S., where our products are manufactured, to enjoy the benefits realized currently by many patients overseas," said Andrew I. Sealfon, president of the company, based in Chester, NY.  "Although we use a needle which is smaller in gauge than many needles being used for subcutaneous administration of certain drugs, our design results in flow rates comparable to, or better than, the flow rates of the larger needles.  This can result in less pain and discomfort for the patient, less insertion difficulty for the patient and medical personnel, and shorter infusion times," Sealfon added.

The needle sets are an ideal companion for RMS Medical Products' FREEDOM60® Syringe Infusion System, which has enhanced the lifestyle of numerous patients requiring regular drug infusions due to its portability and ease of use.  FREEDOM60® enjoys widespread use by ambulatory patients at home as well as those in healthcare facilities.  "Even though the RMS Subcutaneous Needle Sets provide advanced fluidics, the pricing will be highly competitive, just as FREEDOM60® has been in the infusion pump market," Sealfon said.

The RMS Subcutaneous Needle Sets use custom designed, approximately 26-gauge needles, which have a smaller outside diameter than commonly used 24-gauge needles.  This translates into less "ouch" when the needles are inserted, and greater comfort throughout lengthy infusions.  The sets have superior fluidics resulting in faster flow rates.  When used in multi-needle sets, as typically is the case for subcutaneous immune globulin infusions, the RMS Subcutaneous Needle Sets distribute equal volumes of drug to all needles.  The sets are available in single, double, triple, and quad configurations.  RMS produces a low residual "Y" connector, which allows up to eight needles to be used for a single infusion.  Needles lengths currently available are 6mm, 9mm, and 12mm.

"We believe that patients who may be fearful of needles, or are uncomfortable with the thought of having to undergo lengthy infusions, will appreciate the potential benefits, as will health care providers," Sealfon concluded.

RMS Medical Products is the manufacturer of the FREEDOM60® Syringe Infusion System and the RES-Q-VAC® hand powered suction device.  A primary use for the FREEDOM60® Syringe Infusion Pump is in subcutaneous administration of immune globulin due to its safe, controlled pressure and ability to adjust automatically to the flow.  The inherently safe pressures used to deliver drugs to patients minimize discomfort, swelling and other complications sometimes found with conventional electric infusion devices.  There are additional applications such as the delivery of antibiotics for the ambulatory patient.

Forward Looking Statements

Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical facts, may be forward-looking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  These statements involve risks and uncertainties that could cause actual results to differ materially from those included in forward-looking statements due to a variety of factors.  More information about these factors can be found in Repro-Med's latest Annual Report filed with Securities and Exchange Commission on Form 10-K.  The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Andrew I. Sealfon, President
RMS Medical Products
24 Carpenter Road, Chester, NY 10918
Telephone: (845) 469-2042
FAX:  (845) 469-5518


'/>"/>
SOURCE Repro-Med Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Injectable Gel to Treat Fecal Incontinence
2. FDA approves Incivek for hepatitis C
3. FDA Approves Sutent for Rare Type of Pancreatic Cancer
4. FDA Approves New HIV Treatment
5. FDA Approves Victrelis for Hepatitis C
6. FDA Approves New Treatment for Rare Type of Pancreatic Cancer
7. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
8. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
9. FDA Approves New Treatment for Type 2 Diabetes
10. FDA Approves Zytiga for Late-Stage Prostate Cancer
11. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research and ... Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" ... ... 2021 from its current market size in 2016. The Untapped Proton Therapy ... than 1 Billion USD in 2016. Proton Therapy plays ...
(Date:3/29/2017)...  Zynex (OTCQB: ZYXI), an innovative medical technology company specializing ... for pain management, stroke rehabilitation, cardiac monitoring and neurological ... 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 a.m. ... expects to file its 2016 full year financial results ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 30, 2017 , ... Grass pollen is the main cause of hay ... the stuff. The season for grass pollen runs from May to July each year; with ... fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and ... two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, ...
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
Breaking Medicine News(10 mins):